Inflammatory bowel disease questions love to test whether you can connect symptoms + complications + targeted therapy—and then punish you for picking a “reasonable-sounding” immunosuppressant that’s wrong for the specific scenario. The fastest way to stop missing these is to treat every answer choice like it’s trying to teach you something (because it is).
The Vignette (USMLE-Style)
A 28-year-old woman has Crohn disease with persistent abdominal pain and non-bloody diarrhea despite treatment with mesalamine and a course of prednisone. Colonoscopy shows skip lesions and aphthous ulcers. She also reports painful, draining lesions in the perianal area consistent with fistulas. Labs show mild anemia and elevated CRP. She is screened and found to have a negative TB test and no evidence of chronic hepatitis B.
Which medication is the best next step to induce and maintain remission?
A. Infliximab
B. Azathioprine
C. Vedolizumab
D. Ustekinumab
E. Ciprofloxacin
Step-by-Step: What’s Being Tested?
This stem is screaming two key ideas:
1) This is moderate-to-severe Crohn disease
- Symptoms persist despite mesalamine + steroids
- Elevated inflammatory markers
- Endoscopic inflammation
2) There’s fistulizing perianal disease
- One of the most testable indications for anti–TNF-α therapy
- Anti-TNF agents have strong evidence for closing fistulas and inducing remission
✅ Correct Answer: A. Infliximab (or Adalimumab)
Why it’s correct
Infliximab (and adalimumab) are anti–TNF-α monoclonal antibodies used for:
- Moderate-to-severe Crohn disease
- Ulcerative colitis (moderate-to-severe)
- Fistulizing Crohn (high yield)
- Steroid-refractory or steroid-dependent disease
Mechanism (high-yield)
- Binds and neutralizes TNF-α, reducing inflammatory cytokine signaling and leukocyte recruitment.
What Step loves to ask (must-know adverse effects)
Before starting anti-TNF therapy, screen for:
- Tuberculosis (reactivation risk; granuloma maintenance depends on TNF-α)
- Hepatitis B (reactivation risk)
- Also know:
- Serious infections (esp. opportunistic)
- Infusion reaction (more with infliximab; it’s IV)
- Drug-induced lupus–like syndrome (anti-dsDNA/ANA)
- Possible increased risk of certain malignancies (classically mentioned: lymphoma; rare hepatosplenic T-cell lymphoma in young males on combo therapy)
Infliximab vs Adalimumab (quick compare)
| Drug | Route | Antibody type | Typical use-case test writers hint at |
|---|---|---|---|
| Infliximab | IV infusion | Chimeric (mouse-human) | Hospital/infusion center; infusion reactions |
| Adalimumab | Subcutaneous | Fully human | Outpatient self-injection |
Why Every Other Choice Is Wrong (and What It Really Tests)
B. Azathioprine — Wrong as the best next step here
What it is: Thiopurine immunomodulator (prodrug → 6-MP) that decreases purine synthesis → ↓ lymphocyte proliferation.
Why it’s tempting: It’s used in IBD, so it “sounds right.”
Why it’s wrong here:
- Slow onset (weeks to months). Not ideal when you need effective induction in moderate-to-severe/fistulizing Crohn.
- More commonly used for maintenance (often as a steroid-sparing agent) and sometimes combined with biologics to reduce anti-drug antibodies.
High-yield toxicities:
- Bone marrow suppression
- Hepatotoxicity
- Pancreatitis
- Risk increases with low/absent TPMT activity (Step classic)
C. Vedolizumab — Not first-line for fistulizing disease on exams
What it is: Monoclonal antibody against α4β7 integrin → blocks lymphocyte trafficking to gut (MAdCAM-1 mediated).
Why it’s tempting: It’s “IBD-specific” and sounds targeted.
Why it’s wrong (in this stem):
- Anti-TNF agents are the classic testable go-to for fistulizing Crohn.
- Vedolizumab is great for moderate-to-severe UC/Crohn, especially when you want a more gut-selective immunosuppressant, but on many Step-style questions, anti-TNF is the best answer when fistulas are highlighted.
High-yield pearl:
- Much lower systemic immunosuppression vs anti-TNF (gut-selective), and importantly not associated with PML in the way natalizumab is.
D. Ustekinumab — Reasonable option, but not the “most classic” for this vignette
What it is: Monoclonal antibody against IL-12/IL-23 (binds p40 subunit).
Why it’s tempting: It’s used for Crohn and is increasingly common in practice.
Why it’s wrong in this question’s logic:
- For boards, anti-TNF therapy is the classic first biologic for moderate-to-severe Crohn with perianal fistulas, especially after steroid failure.
- Ustekinumab is often used when:
- Anti-TNF fails or is not tolerated
- Patient has comorbid psoriasis (also treated by ustekinumab)
High-yield association:
- Also used for psoriasis/psoriatic arthritis—Step may test “one drug, two diseases.”
E. Ciprofloxacin — Helpful adjunct, not the main immunologic treatment
What it is: Fluoroquinolone antibiotic (inhibits DNA gyrase/topoisomerase II).
Why it’s tempting: Perianal disease + drainage makes people think “infection.”
Why it’s wrong:
- Antibiotics can be used as adjuncts in perianal Crohn (often metronidazole and/or ciprofloxacin), particularly if there’s concern for abscess or secondary infection.
- But antibiotics do not treat the underlying immune-driven inflammation that’s driving fistulas and luminal disease.
High-yield fluoroquinolone toxicities:
- Tendonitis/tendon rupture
- QT prolongation
- Peripheral neuropathy
- Worsening myasthenia gravis
The “Q-Bank Pattern” to Recognize
When you should think Infliximab/Adalimumab
Pick anti-TNF (especially for Crohn) when you see:
- Fistulas (perianal drainage, recurrent abscesses, setons in history)
- Steroid-refractory or steroid-dependent IBD
- Moderate-to-severe disease with systemic inflammation (↑ CRP/ESR, weight loss)
- Extraintestinal manifestations that track with bowel activity (e.g., erythema nodosum)
When not to pick anti-TNF
Watch for stems that hint at:
- Untreated latent TB or high TB risk with no screening
- Chronic hepatitis B without prophylaxis
- Serious active infection/sepsis
High-Yield One-Liners (Step 1 & Step 2)
- Anti–TNF-α (infliximab, adalimumab): Crohn/UC biologics; best-known for fistulizing Crohn.
- Major risks: TB reactivation, HBV reactivation, serious infections; infliximab can cause infusion reactions.
- Azathioprine/6-MP: maintenance/steroid-sparing; slow onset; toxicity includes myelosuppression, hepatotoxicity, pancreatitis; related to TPMT.
- Vedolizumab: gut-selective anti-integrin (α4β7); useful for UC/Crohn with less systemic immunosuppression.
- Ustekinumab: IL-12/23 inhibitor; Crohn + psoriasis; often after anti-TNF failure/intolerance.
Rapid-Fire Table: IBD Biologics & Buzzwords
| Class | Drug | Target | Board-style clue | Big risk to remember |
|---|---|---|---|---|
| Anti-TNF | Infliximab, Adalimumab | TNF-α | Fistulas, severe Crohn/UC | TB/HBV reactivation, infections |
| Anti-integrin | Vedolizumab | α4β7 integrin | Gut-selective IBD biologic | Fewer systemic effects |
| Anti–IL-12/23 | Ustekinumab | IL-12/23 (p40) | Crohn + psoriasis | Infections (less classic than anti-TNF) |
Takeaway: “Best Next Step” Means Best for This Phenotype
In moderate-to-severe Crohn with perianal fistulas, the question is usually testing whether you know that anti-TNF therapy (infliximab/adalimumab) is the most classic, high-yield biologic to induce remission and promote fistula closure—after you’ve ruled out TB/HBV.